Diabetes Care:母体BMI和血糖影响胎儿的代谢组学!

2017-06-26 MedSci MedSci原创

近期,一项发表在杂志Diabetes Care上的研究使用目标代谢组学来确定母体BMI和葡萄糖水平与脐带血代谢物以及脐带血代谢物与新生儿出生体重和母亲后代胎儿肥胖的关系。此项研究对来自欧洲血统、非洲裔加勒比海、泰国和墨西哥裔美国的新生儿(每个祖谱系的400名),其母亲参加高血糖和不良妊娠结局(HAPO)的研究,脐血样本进行靶向代谢组学测定,他哦你是进行了出生时的人体测量。此项研究结果显示:除了甘油

近期,一项发表在杂志Diabetes Care上的研究使用目标代谢组学来确定母体BMI和葡萄糖水平与脐带血代谢物以及脐带血代谢物与新生儿出生体重和母亲后代胎儿肥胖的关系。


此项研究对来自欧洲血统、非洲裔加勒比海、泰国和墨西哥裔美国的新生儿(每个祖谱系的400名),其母亲参加高血糖和不良妊娠结局(HAPO)的研究,脐血样本进行靶向代谢组学测定,他哦你是进行了出生时的人体测量。

此项研究结果显示:除了甘油三酯、天冬酰胺/天冬氨酸、精氨酸和酰基肉碱C14-OH / C12-DC之外,四个队列的Meta分析显示了在妊娠28周时分析的所有脐带血代谢物与相同代谢物的母体禁食水平有显着的相关性。

Meta分析还表明,母体有或没有调整母体葡萄糖的BMI与脐带血代谢物,包括支链氨基酸及其代谢产物以及苯丙氨酸有关。

1小时但不是空腹的葡萄糖与脐带血3-羟基丁酸酯及其肉碱酯,中链酰基肉碱和甘油有关。一些脐带血代谢物与新生儿出生体重和皮肤褶皱相关,包括甘油三酸酯(负相关)和3-羟基丁酸酯、其肉碱酯和丝氨酸的正相关。

此项研究表明:产妇BMI和血糖与新生儿代谢组学的不同组成部分相关,与其对出生时新生儿大小的独立影响相一致。母体BMI与成年人胰岛素抵抗和2型糖尿病风险的新生代谢特征相关。

原始出处:
Lowe WL Jr, Bain JR, et al. Maternal BMI and Glycemia Impact the Fetal Metabolome. Diabetes Care. 2017 Jul;40(7):902-910. doi: 10.2337/dc16-2452.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760056, encodeId=3ae11e600567d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 17:46:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637855, encodeId=1ec0163e8551b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 05:46:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901699, encodeId=f0d8190169925, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Aug 01 06:46:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480275, encodeId=7a2614802e524, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Jun 28 08:46:00 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760056, encodeId=3ae11e600567d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 17:46:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637855, encodeId=1ec0163e8551b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 05:46:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901699, encodeId=f0d8190169925, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Aug 01 06:46:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480275, encodeId=7a2614802e524, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Jun 28 08:46:00 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760056, encodeId=3ae11e600567d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 17:46:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637855, encodeId=1ec0163e8551b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 05:46:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901699, encodeId=f0d8190169925, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Aug 01 06:46:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480275, encodeId=7a2614802e524, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Jun 28 08:46:00 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760056, encodeId=3ae11e600567d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Nov 12 17:46:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637855, encodeId=1ec0163e8551b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 05:46:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901699, encodeId=f0d8190169925, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Aug 01 06:46:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480275, encodeId=7a2614802e524, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Wed Jun 28 08:46:00 CST 2017, time=2017-06-28, status=1, ipAttribution=)]

相关资讯

PLOS MED:估计BMI对帕金森病风险的影响

在观察性研究中已经报道了高体质指数(BMI)和帕金森病(PD)之间的正相关和负相关,但是由于残留混杂或反向因果关系的可能性,难以确定因果关系。据我们所知,孟德尔随机化(MR) - 使用遗传工具变量(IVs)来探索因果效应 - 是以前没有用于测试BMI对PD的影响的。在这项使用双样本MR的大型研究中,我们发现已知影响BMI的变异体以与更高BMI相一致的方式对PD有影响,导致PD风险降低。这种明显的保

SCI REP:急性缺血性卒中后体重指数与死亡率和功能预后之间的关系!

由此可见,在缺血性卒中患者中,超重或肥胖与死亡率降低或更好的功能恢复并不相关,但体重过低可以预测不良预后。

KIDNEY INT:体重指数增加是终末期肾病的危险因素!

因此,在一般人群中BMI本身是ESRD的一个危险因素,这种相关性是存在于那些没有预先存在的糖尿病、高血压、冠心病和卒中的个人。

EUR HEART J:青少年的体重与早期心脏衰竭风险之间的关系

研究发现,在正常体重已经可以检测到早期心衰的风险大大增加,并且在最高体重者中这一风险增加了近10倍。考虑到目前肥胖症的流行,未来年轻人的心脏衰竭可能会大幅度增加,医生们需要意识到这一点。

Circulation:BMI对先天性心脏病患者手术风险的影响

肥胖或体重过轻都会增加心脏外科手术不良后果的风险,体重系数能否成为围术期不良后果的一项可改变的危险因素,还有待未来进一步研究发现。

PLoS MED:BMI对帕金森发病的影响

在以前的报道中我们已经发现BMI指数偏高对于帕金森(PD)的发病有关,但是具体是保护性因素还是危险因素目前还没有定论。最近,有一项研究采用了孟德尔随机化(MR)设计探索了BMI与帕金森之间的因果关系。